Quick Answer
Mirum Pharmaceuticals, Inc. reported Stockholders Equity of $314.69 million for the year ending 2025.
- Mirum Pharmaceuticals, Inc. showed an increase of +39.5% in Stockholders Equity from 2024 to 2025.
- This data is from Mirum Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2018 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2018: -$10.0 thousand | Q3 2018: -$76.0 thousand | Q1 2019: -$23.05 million | Q2 2019: -$34.94 million | Q3 2019: $146.20 million | Q1 2020: $156.12 million | Q2 2020: $136.21 million | Q3 2020: $120.26 million | Q1 2021: $133.88 million | Q2 2021: $95.74 million | Q3 2021: $56.40 million | Q1 2022: $108.93 million | Q2 2022: $110.69 million | Q3 2022: $169.30 million | Q1 2023: $141.15 million | Q2 2023: $78.61 million | Q3 2023: $269.08 million | Q1 2024: $234.60 million | Q2 2024: $228.99 million | Q3 2024: $232.02 million | Q1 2025: $233.26 million | Q2 2025: $255.16 million | Q3 2025: $292.05 million.
- Historical annual values: Fiscal year 2025: $314.69 million | Fiscal year 2024: $225.64 million | Fiscal year 2023: $248.67 million | Fiscal year 2022: $142.04 million | Fiscal year 2021: $120.21 million | Fiscal year 2020: $172.10 million | Fiscal year 2019: $130.35 million | Fiscal year 2018: -$17.31 million | Fiscal year 2018: $0.00.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: